Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true

https://doi.org/10.20996/1819-6446-2016-12-4-465-470

Full Text:

Abstract

Atrial fibrillation (AF) – is the most common tachyarrhythmia, which is diagnosed in 1-2% of the population. Non-valvular AF increases the risk of ischemic stroke in 5-7 times. More than 50% of thromboembolism originating from the heart is associated with non-valvular AF. Therefore, prevention of ischemic stroke and systemic embolism is one of the main aims of AF treatment. For a long time for prevention of them oral anticoagulants were used mainly from the group of vitamin K antagonists, most often warfarin. In connection with the known disadvantages of warfarin use, the elaboration of new oral anticoagulants (NOAC) became very important in clinical practice. The article presents a contemporary view of the advantages of the NOAC, indications and contraindications for their use. The international recommendations on their use in different clinical situations are analyzed. At the same time, the article deals with some questionable matters of antithrombotic therapy with NOAC at AF and authors give their point of view on a number of studies in the field of clinical arrhythmology. Currently, according to the authors, it is appropriate to speak of a differentiated approach to the appointment of the NOAC, that depends on a whole range of clinical factors, and the results of laboratory and instrumental investigations, rather than to compare these anticoagulants on the principle of "better or worse", as these estimates are not correct, and sometimes they are clearly far from the principles of medical ethics.

About the Authors

Yu. A. Bunin
Russian Medical Academy of Postgraduate Education
Russian Federation
Barrikadnaya ul. 2/1, Moscow, 123995


S. V. Miklishanskaya
Russian Medical Academy of Postgraduate Education
Russian Federation
Barrikadnaya ul. 2/1, Moscow, 123995


References

1. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12(10):1360-420.

2. 2014AHA/ACC/HRS guideline forthe management of patients with atrialfibrillation. Circulation 2014; 130: 272-274.

3. Vanassche T., Lauw M.N., Eikelboom J.S. et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2014; 36: 281-8.

4. Update EuropeanHeart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17:1467-1507.

5. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651.

6. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). Circulation 2011; 123: 1144-50.

7. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. RE-LY steering committee and investigators. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.

8. Patel M.R., Mahaffey K.W., Gard J. et al. Rivaroxaban vs warfarin in non-valvular atrial fibrillation. NEngl J Med 2011; 365: 883-91.

9. Granger C.B., Alexander J.H., Mc Murray J.J. et al. ARISTOTLE committees and investigators. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.

10. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal 2012; 33: 2719-2747.

11. Uchino K.,HernandesA.V.Dabigatran association with higerrisk of acute coronary events: meta-analysis of noninferiorityrandomised controlled trials. Arch Intern Med 2012; 172: 397-402.

12. FDAdrug safety communication regarding pradaxa.Available at: http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm. Checked by 12.06.2016.

13. Dewide W.J., Oirbans T., Verheugt F.W. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention. Lancet 2013; 381: 1107-15.

14. 2014 ESC/EACTS Guidelines on myocardialrevascularization. EuropeanHeartJournal 2014; 35: 2541-2619.

15. Mega J.L., Braunwald E., Wiviott S.D. et al. Rivaroxaban in patients with recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.

16. Oldren J., BudajA., Granger C.B. et al.Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy. Eur Heart J 2011; 32: 2781-9.

17. AlexanderJ.H., Lopes R.D.,James S. et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708.

18. Nieuwlaat R., Eurling L.W., Cleland J.G. et al. Atrial fibrillation and heart failure in cardiology practice. Results of the Euro Heart Survey on atrial fibrillation. J Am CollCardiol 2009; 53: 1690-8.

19. Ferreira J., Ezekowitz M.D., Connolly S.J. et al. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail 2013;15:1053-61.

20. Nagarakanti R., Ezekowitz M.D., Oldgren J. et al. Dabigatran versus warfarin in patients with atrial fibrillation: analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-6.

21. Piccini J.P., Stevens S.R., Lokhnygina Y. et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET-AF trial.J Am CollCardiol 2013; 61: 1998-2006.

22. Flaker G., Lopes R.D.,Al-Khatib S.M. et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation (ARISTOTLE Trial). J Am Coll Cardiol 2014; 63: 1082-7.

23. Cappato R., Ezekowitz M.D., Klein A.L. Rivaroxaban vs vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014; 35: 3346-55.

24. Horstmann S., Zugck C., Krumsdorf U. Left atrial appendage occlusion in atrialfibrillation afterintracranial hemorrage. Neurology 2014; 82: 135-8.

25. Taylor D.W., Barnett H.J., Haynes R.B. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. Lancet 1999; 353: 2179-84.


For citation:


Bunin Y.A., Miklishanskaya S.V. Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true. Rational Pharmacotherapy in Cardiology. 2016;12(4):465-470. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-4-465-470

Views: 358


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)